The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact
Authors:
- 18 December 2009
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 89 (5) , 437-446
Abstract
Chemokines are centrally involved in leukocyte migration, homing and haematopoiesis. Besides these physiological aspects, their role in pathological processes especially with respect to solid tumour and haematological neoplasias is well established. In this context, the focus was set here on disclosing their contribution in B cell chronic lymphocytic leukaemia (B-CLL), which is regarded as the most characteristic low-grade lymphoma. Up to now, it has been demonstrated that several chemokines are involved in migration of B-CLL cells to lymph nodes, secondary lymphoid organs and bone marrow. Moreover, some chemokines are known to have an anti-apoptotic effect and thus contribute to the survival of B-CLL cells. By interfering with both of these aspects, new therapeutic targets for this yet incurable disease may be developed. Furthermore, a correlation can be drawn between the concentration of some chemokines in patients’ serum, the expression of their respective receptors on B-CLL cells and well-established predictive clinical parameters. Consequently, further systematic investigation of the chemokine network may lead to the identification of new diagnostic and prognostic markers. This review focuses on the impact of chemokines and their receptors on B-CLL pathophysiology and points out potential implications for both treatment and diagnosis.Keywords
This publication has 76 references indexed in Scilit:
- Chemokine receptor antagonists: overcoming developmental hurdlesNature Reviews Drug Discovery, 2008
- Role of chemokines in tumor growthCancer Letters, 2007
- IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survivalProceedings of the National Academy of Sciences, 2007
- A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agentsPeptide Science, 2006
- Modulation of the Inflammatory Response in Cardiovascular DiseaseHypertension, 2004
- Balanced responsiveness to chemoattractants from adjacent zones determines B-cell positionNature, 2002
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998
- Expression of the Chemokine Receptor BLR2/EBI1 Is Specifically Transactivated by Epstein-Barr Virus Nuclear Antigen 2Biochemical and Biophysical Research Communications, 1995